» Authors » Simon Hohenester

Simon Hohenester

Explore the profile of Simon Hohenester including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 46
Citations 1194
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Li J, Yao S, Zimny S, Koob D, Jin H, Wimmer R, et al.
Commun Biol . 2024 Nov; 7(1):1591. PMID: 39609606
Cholestatic liver diseases, accompanied by the hepatic accumulation of bile salts, frequently lead to liver fibrosis, while underlying profibrogenic mechanisms remain incompletely understood. Here, we evaluated the role of extracellular...
2.
Cai X, Thorand B, Hohenester S, Prehn C, Cecil A, Adamski J, et al.
Front Endocrinol (Lausanne) . 2023 Oct; 14:1223162. PMID: 37900132
Background: Sex hormones and sex hormone-binding globulin (SHBG) may play a role in fatty liver development. We sought to examine the association of various endogenous sex hormones, including testosterone (T),...
3.
Ye L, Ziesch A, Schneider J, Ofner A, Niess H, Denk G, et al.
Aging Dis . 2023 Jun; 15(1):338-356. PMID: 37307826
Primary sclerosing cholangitis (PSC) represents a chronic liver disease characterized by poor prognosis and lacking causal treatment options. Yes-associated protein (YAP) functions as a critical mediator of fibrogenesis; however, its...
4.
Zimny S, Bourhis H, Weber S, Reiter F, Hohenester S, Kraft E, et al.
Orphanet J Rare Dis . 2023 May; 18(1):122. PMID: 37226184
Background: Wilson disease (WD) is a rare, hereditary disorder of copper metabolism. Due to its variable symptoms and manifestations, diagnosis remains challenging. Affected patients must obtain lifelong medical treatment, as...
5.
Einer C, Munk D, Park E, Akdogan B, Nagel J, Lichtmannegger J, et al.
Gastroenterology . 2023 Mar; 165(1):187-200.e7. PMID: 36966941
Background & Aims: Excess copper causes hepatocyte death in hereditary Wilson's disease (WD). Current WD treatments by copper-binding chelators may gradually reduce copper overload; they fail, however, to bring hepatic...
6.
Cai X, Thorand B, Hohenester S, Koenig W, Rathmann W, Peters A, et al.
Nephrol Dial Transplant . 2022 Sep; 38(5):1240-1248. PMID: 36150717
Background: We aimed to evaluate the relationship of fatty liver, estimated by the fatty liver index (FLI), with kidney function and chronic kidney disease (CKD) in a German cohort study,...
7.
Zimny S, Koob D, Li J, Wimmer R, Schiergens T, Nagel J, et al.
Cells . 2022 Aug; 11(15). PMID: 35954188
Bile salts accumulating during cholestatic liver disease are believed to promote liver fibrosis. We have recently shown that chenodeoxycholate (CDC) induces expansion of hepatic stellate cells (HSCs) in vivo, thereby...
8.
Bischoff M, Zimny S, Feiner S, Sauter J, Sydor S, Denk G, et al.
Eur J Nutr . 2022 Mar; 61(5):2725-2735. PMID: 35277756
Purpose: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. Particularly morbidly obese patients are at risk of developing progressive liver disease. Nutritional and lifestyle intervention...
9.
Cai X, Rospleszcz S, Mensel B, Schminke U, Kuhn J, Aghdassi A, et al.
BMJ Open Gastroenterol . 2021 Oct; 8(1). PMID: 34593525
Objective: It is still controversial if increased hepatic fat independently contributes to cardiovascular risk. We aimed to assess the association between hepatic fat quantified by MRI and various subclinical vascular...
10.
Reiter F, Ye L, Ofner A, Schiergens T, Ziesch A, Brandl L, et al.
Cell Mol Gastroenterol Hepatol . 2021 Sep; 13(1):95-112. PMID: 34537439
Background & Aims: Progression of chronic liver disease (CLD) to liver cirrhosis and liver cancer is a major global cause of morbidity and mortality. Treatment options capable of inhibiting progression...